Meander Medical Center
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The Pulmonology department at Meander Medical Center is leveraging cutting‑edge imaging and therapeutic tools to enhance early detection and monitoring of cancer and blood‑related disorders.
- Advanced PET/CT imaging for lung cancer
- Innovative diagnostic biomarkers for hematologic malignancies
- Evaluation of novel therapeutic devices in oncology
Ongoing studies assess the performance and prognostic value of new imaging agents, aiming to improve disease‑free survival and guide personalized treatment decisions across multiple tumor types.
Hemic and Lymphatic Diseases
Research at this site focuses on high‑impact blood cancers, including Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia and Diffuse Large B‑Cell Lymphoma, with an emphasis on targeted and immunologic therapies.
- Targeted FLT3 inhibition in AML
- Combination immunotherapy for relapsed Hodgkin lymphoma
- MRD‑guided treatment strategies in CLL
- High‑risk DLBCL consolidation approaches
The trials aim to increase disease‑free survival, extend progression‑free intervals, and reduce relapse rates by integrating novel agents and consolidation strategies.
Neoplasms
The center’s oncology portfolio includes solid‑tumor investigations such as non‑small cell lung cancer and colon carcinoma, exploring both therapeutic innovations and adjunctive preventive measures.
- Adjuvant aspirin therapy in colon cancer
- Immunotherapy consolidation in high‑grade B‑cell lymphoma
- PET/CT imaging biomarkers in lung cancer
- Combination regimens for relapsed Hodgkin lymphoma
These studies seek to improve overall survival and long‑term disease control by testing new drug combinations, evaluating maintenance approaches, and refining diagnostic accuracy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 212 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 211 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Merck Sharp & Dohme LLC8active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Meander Medical Center
lock Showing 1 of 104 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of Rituximab and Cyclophosphamide Versus Rituximab Monotherapy in Patients with ANCA-Associated Vasculitis | Leids Universitair Medisch Centrum (LUMC) | Phase III | Recruiting | May 2019 | — |
IMP list
lock Showing 1 of 212 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 13 | Unknown | 2016-07-25 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.